Literature DB >> 9247295

Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins.

A G Aprikian1, L Tremblay, K Han, S Chevalier.   

Abstract

Bombesin-like peptides, including the mammalian homologue gastrin-releasing peptides, are highly expressed and secreted by neuroendocrine cells in prostate carcinoma (PCa) tissues and are likely to be related to the progression of this disease. In the present study, we show that bombesin enhances the migration of androgen-independent PCa cells (PC-3) in vitro, while not affecting their adhesion to extracellular matrix proteins. The bombesin-increased motility of PC-3 cells occurs through its receptor, and, as shown with inhibitors, it likely requires activation of both protein tyrosine kinases (PTKs) and protein kinases C (PKCs). Because the focal adhesion kinase pp125FAK plays a key role in adhesion/motility and is highly expressed in advanced PCa, we examined whether in PC-3 cells bombesin signal transduction triggers the tyrosine phosphorylation of this PTK and of associated integrins and signaling proteins likely to be present in focal adhesion plaques. pp125FAK tyrosine phosphorylation was stimulated by bombesin and mimicked by PKC activation with the tumor-promotor phorbol 12-myristate-13-acetate (PMA). Moreover, this effect of bombesin on pp125FAK tyrosine phosphorylation requires the presence of both active PKC and cytoskeleton integrity since this signal was abolished by down-regulating PKCs induced by prolonged PMA treatment or by PKC inhibition with GF 109203X, as well as by disruption of the cytoskeleton with cytochalasin D. We also show that bombesin increases the tyrosine phosphorylation of a 95-kDa protein (pp95) which was co-immunoprecipitated with the alpha v and beta (3 and 5) subunits, forming integrin receptors with alpha v in PC-3 cells. The protein pp95 is distinct from the endogenously tyrosine-phosphorylated beta3 subunit. In addition, upon bombesin treatment, the beta1, beta3 and beta5 integrin subunits co-immunoprecipitated with pp125FAK and major phosphotyrosine (pY)-containing proteins of 125 and 68-70 kDa, likely corresponding to pp125FAK and paxillin. Together our data suggest that, in addition to PKC activation, tyrosine phosphorylation of pp125FAK and integrin-associated proteins may play an important role in bombesin signaling, triggering the processes of PCa cell motility and invasion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247295     DOI: 10.1002/(sici)1097-0215(19970729)72:3<498::aid-ijc19>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  The role of alpha(v)beta(3) in prostate cancer progression.

Authors:  Carlton R Cooper; Christopher H Chay; Kenneth J Pienta
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 3.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  ADP-ribosylation factor 6 regulates actin cytoskeleton remodeling in coordination with Rac1 and RhoA.

Authors:  R L Boshans; S Szanto; L van Aelst; C D'Souza-Schorey
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

5.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.

Authors:  M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 6.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

7.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

8.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

9.  Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.

Authors:  Shibu Thomas; Maurizio Chiriva-Internati; Girish V Shah
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

10.  Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.

Authors:  Jing Fang; Yong Lu; Kedong Ouyang; Guojun Wu; Huiyong Zhang; Yanhua Liu; Yingying Chen; Ming Lin; Huaqian Wang; Liang Jin; Rongyue Cao; Rouel S Roque; Li Zong; Jingjing Liu; Taiming Li
Journal:  Clin Vaccine Immunol       Date:  2009-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.